Mesoblast (NASDAQ:MESO - Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating in a research report issued on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Mesoblast's FY2025 earnings at ($0.70) EPS.
MESO has been the subject of several other reports. Piper Sandler restated an "overweight" rating and set a $24.00 price target (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Jefferies Financial Group cut Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Mesoblast has an average rating of "Moderate Buy" and an average target price of $18.00.
Check Out Our Latest Research Report on Mesoblast
Mesoblast Stock Performance
Shares of MESO stock traded down $0.21 during trading hours on Tuesday, hitting $13.47. The company had a trading volume of 497,135 shares, compared to its average volume of 797,639. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The company's fifty day moving average is $17.77 and its 200 day moving average is $12.38. Mesoblast has a fifty-two week low of $2.05 and a fifty-two week high of $22.00.
Institutional Trading of Mesoblast
A number of large investors have recently modified their holdings of MESO. Lindbrook Capital LLC boosted its holdings in Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after purchasing an additional 901 shares during the period. GAMMA Investing LLC boosted its stake in shares of Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock valued at $133,000 after buying an additional 1,213 shares during the period. R Squared Ltd acquired a new position in shares of Mesoblast during the fourth quarter worth about $30,000. Prosperity Wealth Management Inc. increased its stake in shares of Mesoblast by 2.0% during the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company's stock worth $1,846,000 after buying an additional 1,795 shares during the period. Finally, Quadrant Capital Group LLC raised its holdings in Mesoblast by 41.1% in the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after acquiring an additional 1,891 shares in the last quarter. Hedge funds and other institutional investors own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
